WO2005011712A1 - Natural astaxanthin extract reduces dna oxidation - Google Patents
Natural astaxanthin extract reduces dna oxidation Download PDFInfo
- Publication number
- WO2005011712A1 WO2005011712A1 PCT/US2004/024314 US2004024314W WO2005011712A1 WO 2005011712 A1 WO2005011712 A1 WO 2005011712A1 US 2004024314 W US2004024314 W US 2004024314W WO 2005011712 A1 WO2005011712 A1 WO 2005011712A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- astaxanthin
- extract
- natural
- subject
- therapeutically effective
- Prior art date
Links
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 308
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 308
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 306
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 305
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 296
- 239000000284 extract Substances 0.000 title claims abstract description 86
- 230000003647 oxidation Effects 0.000 title description 10
- 238000007254 oxidation reaction Methods 0.000 title description 10
- 238000000034 method Methods 0.000 claims abstract description 101
- 230000008789 oxidative DNA damage Effects 0.000 claims abstract description 31
- 241000168517 Haematococcus lacustris Species 0.000 claims abstract description 19
- 235000021466 carotenoid Nutrition 0.000 claims description 42
- 150000001747 carotenoids Chemical class 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 26
- -1 astaxanthin diesters Chemical class 0.000 claims description 21
- 239000003963 antioxidant agent Substances 0.000 claims description 20
- 235000006708 antioxidants Nutrition 0.000 claims description 19
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 19
- 239000000194 fatty acid Substances 0.000 claims description 19
- 229930195729 fatty acid Natural products 0.000 claims description 19
- 230000003078 antioxidant effect Effects 0.000 claims description 18
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 12
- 235000013734 beta-carotene Nutrition 0.000 claims description 12
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 12
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 12
- 235000012680 lutein Nutrition 0.000 claims description 12
- 229960005375 lutein Drugs 0.000 claims description 12
- 239000001656 lutein Substances 0.000 claims description 12
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 12
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 12
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 12
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 12
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 11
- 239000011648 beta-carotene Substances 0.000 claims description 11
- 229960002747 betacarotene Drugs 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 210000000822 natural killer cell Anatomy 0.000 claims description 11
- MQZIGYBFDRPAKN-UWFIBFSHSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-UWFIBFSHSA-N 0.000 claims description 10
- 150000004665 fatty acids Chemical class 0.000 claims description 10
- 210000002865 immune cell Anatomy 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 9
- 150000005690 diesters Chemical group 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 claims description 6
- 235000012682 canthaxanthin Nutrition 0.000 claims description 6
- 239000001659 canthaxanthin Substances 0.000 claims description 6
- 229940008033 canthaxanthin Drugs 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 5
- 210000004988 splenocyte Anatomy 0.000 claims description 5
- 239000012736 aqueous medium Substances 0.000 claims description 4
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- MQZIGYBFDRPAKN-QHKQXWLXSA-N (6S)-6-hydroxy-3-[(1E,3E,5E,7E,9E,11E,13E,15Z,17E)-18-[(4S)-4-hydroxy-2,6,6-trimethyl-3-oxocyclohexen-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-2,4,4-trimethylcyclohex-2-en-1-one Chemical compound C/C(/C=C/C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-QHKQXWLXSA-N 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 abstract description 4
- 241000168525 Haematococcus Species 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 23
- 239000003921 oil Substances 0.000 description 20
- 241000195493 Cryptophyta Species 0.000 description 19
- 235000005911 diet Nutrition 0.000 description 19
- 230000000378 dietary effect Effects 0.000 description 19
- 235000019198 oils Nutrition 0.000 description 19
- 230000009467 reduction Effects 0.000 description 19
- 150000002148 esters Chemical class 0.000 description 17
- 229910002092 carbon dioxide Inorganic materials 0.000 description 16
- 238000000605 extraction Methods 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 230000004792 oxidative damage Effects 0.000 description 14
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 13
- 210000002381 plasma Anatomy 0.000 description 13
- 239000012530 fluid Substances 0.000 description 12
- 230000001590 oxidative effect Effects 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 11
- 239000003642 reactive oxygen metabolite Substances 0.000 description 11
- 230000005778 DNA damage Effects 0.000 description 10
- 231100000277 DNA damage Toxicity 0.000 description 10
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000005951 type IV hypersensitivity Effects 0.000 description 10
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000000194 supercritical-fluid extraction Methods 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 241000972773 Aulopiformes Species 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 239000008601 oleoresin Substances 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 239000001569 carbon dioxide Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000003927 comet assay Methods 0.000 description 7
- 231100000170 comet assay Toxicity 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 235000019515 salmon Nutrition 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000238557 Decapoda Species 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000003226 mitogen Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000251468 Actinopterygii Species 0.000 description 5
- 241001542817 Phaffia Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 241000277331 Salmonidae Species 0.000 description 5
- 235000019688 fish Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000003859 lipid peroxidation Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 229960001005 tuberculin Drugs 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108010062580 Concanavalin A Proteins 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 102100022339 Integrin alpha-L Human genes 0.000 description 4
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 238000004617 QSAR study Methods 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- PXGPLTODNUVGFL-NAPLMKITSA-N 8-epi-prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-NAPLMKITSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000238424 Crustacea Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 3
- 241000277263 Salmo Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000009360 aquaculture Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 229920001903 high density polyethylene Polymers 0.000 description 3
- 239000004700 high-density polyethylene Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 241000238017 Astacoidea Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108010084313 CD58 Antigens Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 241000195628 Chlorophyta Species 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 2
- 208000030433 Epiphysiolysis of the hip Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 2
- 240000007817 Olea europaea Species 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 229910052776 Thorium Inorganic materials 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 150000001514 astaxanthins Chemical class 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000037416 cystogenesis Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- WGIYGODPCLMGQH-UHFFFAOYSA-N delta-carotene Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C WGIYGODPCLMGQH-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000000835 electrochemical detection Methods 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 235000012661 lycopene Nutrition 0.000 description 2
- 229960004999 lycopene Drugs 0.000 description 2
- 239000001751 lycopene Substances 0.000 description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 2
- 229940033080 omega-6 fatty acid Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000010627 oxidative phosphorylation Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229940097156 peroxyl Drugs 0.000 description 2
- 235000013970 phaffia yeast Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009696 proliferative response Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003760 tallow Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 125000002640 tocopherol group Chemical class 0.000 description 2
- 235000019149 tocopherols Nutrition 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- UBKVUFQGVWHZIR-UHFFFAOYSA-N 8-oxoguanine Chemical compound O=C1NC(N)=NC2=NC(=O)N=C21 UBKVUFQGVWHZIR-UHFFFAOYSA-N 0.000 description 1
- 241000206486 Adonis Species 0.000 description 1
- 241001485474 Adonis amurensis Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- HRQKOYFGHJYEFS-UHFFFAOYSA-N Beta psi-carotene Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C HRQKOYFGHJYEFS-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 101150106671 COMT gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241000195641 Characium Species 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 241000180279 Chlorococcum Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 241001035792 Dictyosphaerium Species 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710081048 Endonuclease III Proteins 0.000 description 1
- 241000239366 Euphausiacea Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108700024827 HOC1 Proteins 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 241000277338 Oncorhynchus kisutch Species 0.000 description 1
- 241000277277 Oncorhynchus nerka Species 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000241627 Pfaffia Species 0.000 description 1
- 241000081271 Phaffia rhodozyma Species 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 241000694540 Pluvialis Species 0.000 description 1
- 240000009305 Pometia pinnata Species 0.000 description 1
- 235000017284 Pometia pinnata Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 101100178273 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HOC1 gene Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000277288 Salmo trutta Species 0.000 description 1
- 241000277293 Salvelinus alpinus Species 0.000 description 1
- 241000195663 Scenedesmus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 101710165202 T-cell surface antigen CD2 Proteins 0.000 description 1
- 241000736687 Trebouxia Species 0.000 description 1
- 241000962283 Turdus iliacus Species 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 238000006993 Weiss annulation reaction Methods 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- IGABZIVJSNQMPZ-UHFFFAOYSA-N alpha-Zeacarotene Natural products CC(C)=CCCC(C)=CCCC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C IGABZIVJSNQMPZ-UHFFFAOYSA-N 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000001745 carotenals Chemical class 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001749 carotenones Chemical class 0.000 description 1
- 235000005472 carotenones Nutrition 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000010638 cranberry seed oil Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- WGIYGODPCLMGQH-ZNTKZCHQSA-N delta-Carotene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C WGIYGODPCLMGQH-ZNTKZCHQSA-N 0.000 description 1
- 235000001581 delta-carotene Nutrition 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 235000000633 gamma-carotene Nutrition 0.000 description 1
- HRQKOYFGHJYEFS-RZWPOVEWSA-N gamma-carotene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C HRQKOYFGHJYEFS-RZWPOVEWSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000013763 haematococcus algae meal Nutrition 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002535 isoprostanes Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000019935 photoinhibition Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 150000004291 polyenes Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 159000000005 rubidium salts Chemical class 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 241001507086 salmonid fish Species 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Definitions
- This disclosure is related to reducing oxidative damage to DNA in cells, particularly in immune cells in mammals. More specifically, this disclosure provides methods of using a natural extract comprising and enriched in astaxanthin to reduce, prevent, or treat oxidative damage to DNA in mammals.
- Sources of oxidative damage are many, and include chemicals present in the environment, aging, disease, intense exercise, and ionizing radiation. Additionally, many products and byproducts of cellular metabolism can cause or contribute to oxidative damage.
- the immune system is a key player in defense against disease and cancer. Unfortunately, the immune system is particularly susceptible to oxidative damage. Immune cells are highly active cells, which undergo rapid division, especially when challenged. The cellular membranes of immune cells contain a high percentage of polyunsaturated fatty acids. Immune cells also generate reactive and highly reactive oxidative agents, which are part of an arsenal used to attack and neutralize various challenges encountered as part of their normal immune activity.
- Astaxanthin is particularly potent in quenching singlet oxygen, and has over five hundred times the ability to quench singlet oxygen as ⁇ -tocopherol. It has a unique molecular structure that gives it powerful antioxidant function. It is extracted from salmon, crustaceans, microalgae, and Phaffia (a yeast, also known as Pfaffia), and it can be chemically synthesized. Summary of the Disclosure It has surprisingly been found that oxidative DNA damage (as measured, for instance, by level of 8-OHdG) can be significantly reduced in a subject, by administering low dosages of a natural astaxanthin enriched extract to the subject.
- the present disclosure therefore provides a method for reducing or inhibiting oxidative DNA damage in a subject, by providing the subject with a therapeutically effective dose of astaxanthin.
- Oral administration is contemplated, for instance in the form of a capsule, tablet, or pill comprising astaxanthin, particularly naturally occurring esterified astaxanthin. It may also be combined with other constituents, such as other antioxidants, vitamins, minerals, drugs, etc. Intravenous administration is also contemplated, for instance when oral administration would not be applicable. It is also contemplated that the astaxanthin can be administered to a subject in or accompanied by a food or beverage substance.
- the natural astaxanthin extract comprises predominantly mono- and di-ester forms of astaxanthin.
- the natural astaxanthin extract comprises no more than about 5% free astaxanthin, about 45-50% astaxanthin monoesters, about 10- 40% astaxanthin diesters, and other carotenoids in the remaining percentage.
- the other carotenoids may be ⁇ -carotene, lutein, canthaxanthin, or a mixture of two or more thereof.
- the natural astaxanthin extract is derived from yeast (such as a Phaffia species) or microalgae (such as Haematococcus pluvialis).
- the astaxanthin in the extract is greater than 95% (3S,3'S) astaxanthin, for instance, as much as about 100% (3S,3'S) astaxanthin.
- the astaxanthin in the extract in some embodiments comprises about 55-62% E-astaxanthin, about 13-18% 9Z- astaxanthin, and about 23-29% 13Z-astxanthin.
- natural astaxanthin extract used in the methods described herein further comprises fatty acids, and the fatty acids are one or more of Laurie, Tridecanoic, Myristic, Pentadecanoic, Palmitic, c _'-9-Palmitoleic, Heptadecanoic, c/s-lO-Heptadecenoic, Stearic, cis-9-Oleic and/or tr w-9-Elaidic, cw-9,12-Linoleic and/or tr ⁇ ra-9,12-Linolelaidic, Arachidic, alpha -Linolenic, czs- 11-Eicosenoic, Linolenic, Heneicosanoic, cw-ll,14-E
- the natural astaxanthin extract are produced by a process comprising supercritical carbon dioxide extraction, particularly supercritical carbon dioxide extraction without the addition of other chemicals that might remain in the extract as contaminants.
- the natural astaxanthin extract is administered to the subject in combination with (either concurrently or in sequence) at least one additional biologically active compound.
- the biologically active compound is a carotenoid, an antioxidant, a vitamin, or a second natural extract.
- the natural astaxanthin extract is dissolved in oil; dispersed in oil; dispersed in an aqueous medium; homogenized in an aqueous medium; encapsulated; processed into dry material (such as stabilized beadlets, a powder, a granule, or a combination of two or more thereof); or a combination of two or more thereof.
- the natural astaxanthin extract is formulated as a liquid, a liquid capsule, a solid capsule or a tablet.
- the natural antioxidant extract is administered to the subject in or with a food or beverage product.
- the therapeutically effective dose astaxanthin reduces the oxidative DNA damage by at least 30%, compared to a subject not administered the therapeutically effective dose of astaxanthin.
- the provided methods are beneficial in that they are effective for reducing, preventing, ameliorating, or reversing oxidative DNA damage in immune cells in the subject.
- the immune cells are cells, B-cells, monocytes, neutrophils, natural killer cells, splenocytes, or a mixture of two or more thereof.
- Therapeutically effective doses in the described methods will vary, but in general an effective dose is about 0.5-1000 mg astaxanthin per day, and most often about 1-10 mg per day. In specific embodiments, the therapeutically effective dose is about 2 mg per day, about 4 mg per day, or about 8 mg per day.
- Figure 1 is a graph showing concentrations of plasma astaxanthin in human subjects fed 0, 2 or 8 mg astaxanthin daily for 8 weeks.
- Figure 2 is a graph showing the response to phytohemagglutinin-induced lymphocyte proliferation in human subjects fed 0, 2 or 8 mg astaxanthin daily for 8 weeks.
- Figure 3 is a graph showing the response to concanavalin A-induced lymphocyte proliferation in human subjects fed 0, 2 or 8 mg astaxanthin daily for 8 weeks.
- Figure 4 is a graph showing the response to pokeweed mitogen-induced lymphocyte proliferation in human subjects fed 0, 2 or 8 mg astaxanthin daily for 8 weeks.
- Figure 5 is a graph showing the natural killer cell cytotoxic activity (1:10) in human subjects fed 0, 2 or 8 mg astaxanthin daily for 8 weeks.
- Figure 6 is a graph showing the percent of total T cells in blood from human subjects fed 0, 2 or 8 mg astaxanthin daily for 8 weeks.
- Figure 7 is a graph showing the percent of B cells in blood from human subjects fed 0, 2 or 8 mg astaxanthin daily for 8 weeks.
- Figure 8 is a graph showing the percent of LFA-1+ (adhesion molecule) cells in blood from human subjects fed 0, 2 or 8 mg astaxanthin daily for 8 wk.
- Figure 9 is a graph showing the response to the delayed type hypersensitivity tuberculin test in human subjects fed 0, 2 or 8 mg astaxanthin daily for 8 weeks,
- Figure 10 is a graph showing concentrations of plasma 8-OHdeoxyguanosine in human subjects fed 0, 2 or 8 mg astaxanthin daily for 8 weeks.
- Figure 11 is a graph showing concentrations of plasma 8-isoprostane in human subjects fed 0, 2 or 8 mg astaxanthin daily for 8 weeks.
- letter notations above certain bars indicate matched statistical significance within that experiment.
- two bars that are marked with the same letter are statistically different from each other at a confidence level of greater than 0.05 (p ⁇ 0.05). Bars marked with different letters are not statistically different at that confidence level.
- Antioxidant A substance that, when present in a mixture containing an oxidizable substrate biological molecule, significantly delays, reduces, reverses or prevents oxidation of the substrate biological molecule. Antioxidants can act by scavenging biologically important reactive free radicals or other reactive oxygen species ( * 0 2 " , H 2 0 2 , * OH, HOC1, ferryl, peroxyl, peroxynitrite, and alkoxyl), or by preventing their formation, or by catalytically converting the free radical or other reactive oxygen species to a less reactive species. Astaxanthin: A carotenoid with a unique molecular structure that gives it powerful antioxidant function.
- Astaxanthin is well known as the pigment providing the pinkish-red hue to the flesh of salmon and trout, as well the coloring in the carapaces of shrimp, lobsters and crayfish.
- the astaxanthin molecule has two asymmetric carbons located at the 3 and 3' positions of the benzenoid rings on either end of the molecule. Different enantiomers of the molecule result from the exact way that the hydroxyl groups (-OH) are attached to the carbon atoms at these centers of asymmetry. When the hydroxyl group is attached so that it projects above the plane of the molecule, it is said to be in the R configuration; when the hydroxyl group projects below the plane of the molecule, it is said to be in the S configuration.
- 3R,3'R Three possible enantiomers of astaxanthin are designated (3R,3'R), (3S,3'S) and (3R,3'S; meso).
- Free astaxanthin and its mono- and diesters from Haematococcus have optically pure (3S,3'S)-chirality.
- Only the (3S,3'S) isomer of astaxanthin is found in the skin and flesh of some salmonid fish. Salmonids are unable to epimerize the 3-hydroxy groups, so it is believed that their dietary carotenoid is also 3S,3'S-astaxanthin.
- HPLC separation of astaxanthin has been used to identify the eggs of escaped salmon, since wild fish contain about 80% astaxanthin and farmed fish fed chemically synthesized astaxanthin contain 35% or less (Lura & Saegrov, Can. J. Fish. Aquat. Sci. 48:429-433, 1991; Turujman et al., J. AOACInt. 80:622-632, 1997).
- the chirality of astaxanthin is believed to influence biological functions of this carotenoid.
- Oxidative Damage Any damage resulting from a variety of oxidative agents such as oxygen itself, hydroxyl radical, hydrogen peroxide, other free radicals, ozone etc., or from any kind of harmful irradiation, such as alpha, beta or gamma rays, neutron radiation, and UVA and UVB irradiation.
- Oxidative agents such as oxygen itself, hydroxyl radical, hydrogen peroxide, other free radicals, ozone etc.
- harmful irradiation such as alpha, beta or gamma rays, neutron radiation, and UVA and UVB irradiation.
- Enantiomers Enantiomers are forms of a molecule that exist as non-superimposable mirror images of one another. Not being able to superimpose one molecule form on top of the other simply means that the two are not equivalent or identical. For a compound to form an enantiomeric pair, it must have chiral molecules. Chiral molecules must not have an internal plane of symmetry, and they
- Enantiomers are also called optical isomers because their solutions rotate the plane of polarized light passing through them. If one enantiomer rotates light in the clockwise direction, a solution of the other enantiomer will rotate it in the opposite direction. Another way to characterize enantiomers is by their configuration. Configuration is the spatial way that non-equivalent groups arrange themselves around a stereocenter carbon. One enantiomer will be configured right handedly (R; rectus) and the other will be configured left handedly (S; sinister). Enantiomers are usually depicted on a planar surface either as a 3-dimensional structural formula or as a Fisher Projection. Free Radicals: Atoms, ions or molecules that contain an unpaired electron.
- ROS Reactive oxygen species
- H 2 0 2 hydroxyl radical
- OH hydroxyl radical
- Other ROS include nitric oxide (NO * ) and peroxy nitrite (NOO * ), and other peroxyl (R0 2 * ) and alkoxyl (RO * ) radicals. Increased production of these poisonous metabolites in certain pathological conditions is believed to cause cellular damage through the action of the highly reactive molecules on proteins, lipids and DNA.
- ROS ROS are believed to accumulate when tissues are subjected to ischemia, particularly when followed by reperfusion.
- Molecular oxygen is essential for aerobic organisms, where it participates in many biochemical reactions, including its role as the terminal electron acceptor in oxidative phosphorylation. Excessive concentrations of various forms of reactive oxygen species and other free radicals can have serious adverse biological consequences, including the peroxidation of membrane lipids, hydroxylation of nucleic acid bases, and the oxidation of sulfhydryl groups and other protein moieties.
- Biological antioxidants include tocopherols and tocotrieneols, carotenoids, quinones, bilirubin, ascorbic acid, uric acid, and metal binding proteins.
- Injectable Composition A pharmaceutically acceptable fluid composition comprising at least an active ingredient.
- the active ingredient is usually dissolved, disseminated, or suspended in a physiologically acceptable carrier, and the composition can additionally comprise minor amounts of one or more non-toxic auxiliary substances, such as emulsifying agents, preservatives, and pH buffering agents and the like.
- non-toxic auxiliary substances such as emulsifying agents, preservatives, and pH buffering agents and the like.
- Natural Astaxanthin Extract An oily, viscous dark red lipophilic extract of an organism that comprises, and preferably produces, astaxanthin, particularly an astaxanthin-rich organism (e.g., Phaffia spp., Haematococcus spp.), which extract contains free astaxanthin, astaxanthin fatty acid mono-esters and astaxanthin fatty acid di-esters along with triglycerides and other lipophilic compounds.
- astaxanthin-rich organism e.g., Phaffia spp., Haematococcus spp.
- Carotenoid pigments found from different sources of Haematococcus pluvialis have been found to have the following typical ranges: Astaxanthin (total) 81-99% (which comprises free astaxanthin 1-5%; astaxanthin monoesters 46-79%; astaxanthin diesters 10- 39%); ⁇ -carotene 0-5%; lutein 1-11%; canthaxanthin 0-5.5%; and other carotenoids 1-9% (Renstrom et al., Phytochemistry 20:2561-2564, 1981: Aquasearch, FDA 75-day Premarket Notification for New Dietary Ingredient for Haematococcus pluvialis algae. Report 65:1 -104, 2000, at page 12).
- Naturally derived astaxanthin exists mainly in the form of the 3S,3'S stereo isomer found in Haematococcus algae or the 3R,3R ! , which is found mainly in Phaffia yeast.
- Synthetic astaxanthin has a more complex stereo isomeric profile due to the non stereo selectivity from the reaction conditions used in its manufacture.
- Haematococcus pluvialis also contains mono and diesterified astaxanthin as the predominant forms of astaxanthin, while Phaffia and synthetically produced astaxanthin substantially lack these esterifications.
- Natural astaxanthin extracts contain astaxanthin in different isomeric forms, the so called and E and Z isomeric configurations. The following provides a summary of the ranges of astaxanthin isomers analyzed in algae preparations from different Haematococcus producers:
- natural astaxanthin extract derived from Haematococcus pluvialis comprises astaxanthin stereoisomers as follows: (3S, 3'S) 100%; (3S, 3'R) and (3R, 3'S) 0 %; (3R,3'R) 0 %, with the geometric isomer proportions, expressed as a percentage of the total astaxanthin, of about: E-astaxanthin 59% ; 9Z- astaxanthin 15%; 13Z-astxanthin 26%, and non-astaxanthin carotenoid levels of about: 0.3% ⁇ -carotene, 0.07% lutein, 0.3% canthaxanthin and 1.3% total other carotenoids.
- the extract will also contain fatty acids.
- the levels and mixture of fatty acids in the extract generally reflect the levels of fatty acids found in the source material.
- the following fatty acids are found in Haematococcus pluvialis and include the following acids: Why, Tridecanoic, Myristic, Pentadecanoic, Palmitic, c s-9-Palmitoleic, Heptadecanoic, c «-10-Heptadecenoic, Stearic, c s-9-Oleic and/or tra «,s-9-Elaidic, c ⁇ -9,12-Linoleic and/or tr r ⁇ -9,12-Linolelaidic, Arachidic, alpha -Linolenic, c/s-l l-Eicosenoic, Linolenic, Heneicosanoic, czs-l l,14
- a natural astaxanthin-enriched extract in the form of an oleoresin will contain from about 1-30% total astaxanthin, for instance, at least about 6-15% astaxanthin, for instance, about 10% astaxanthin.
- the oleoresin also comprises a mixture of naturally occurring fatty acids from the source material.
- examples of the oleoresin will comprise (expressed as the approximate total percent of fatty acids present): Why (0.5 - 0.7), Tridecanoic (0.09 - 0.1) , Myristic (0.51-0.52) , Pentadecanoic (0.03), Palmitic (12.21-13.14), cw-9-Palmitoleic (0.24-0.32), Heptadecanoic ( 0.1- 0.11), cis-10-Heptadecenoic (1.76-1.87), Stearic (0.77-0.79), czs-9-Oleic and/or trara-9-Elaidic (24.14-24.37), cw-9,12-Linoleic and/or zrar ⁇ -9,12-Linolelaidic (30.30-30.68), Arachidic (1.77-1.86
- Phaffia rhodozyma is a form of yeast that also contains astaxanthin. Compared to synthetic astaxanthin and Haematococcus derived astaxanthin, Phaffia- ⁇ e, ⁇ vs ⁇ astaxanthin is different in that it contains predominately the 3R, 3R' stereoisomeric form of astaxanthin (Andrews and Starr, Phytochemistry 15:1003-1007, 1976) and the astaxanthin is present largely in the unesterified form (97%) with an E to Z ratio of about 60:40. By way of example, /z ⁇ -derived astaxanthin enriched extract can be produced using the methods described in Lim et /. (Biochem. Eng.
- Supercritical Fluid Extraction SFE or SCFE: Supercritical fluids are highly compressed gases that combine properties of gases and liquids. Supercritical fluids (e.g., supercritical fluid carbon dioxide) can be used to extract compounds, such as lipophilic or volatile compounds, from samples. Supercritical fluids are inexpensive, contaminant free, less costly to dispose of safely than organic solvents, and have solvating powers similar to organic solvents, but with higher diffusivities, lower viscosity, and lower surface tension.
- the solvating power can be adjusted by changing the pressure or temperature of the extraction process, or by adding modifiers to the supercritical fluid.
- a typical supercritical fluid extractor consists of a tank of the mobile phase, such C0 2 , a pump to pressurize the gas, an oven containing the extraction vessel, a restrictor to maintain a high pressure in the extraction line, and a trapping vessel. Analytes are trapped by letting the solute- containing supercritical fluid decompress into an empty vessel, through a solvent, or onto a solid sorbent material. Examples of extraction systems are dynamic, static, or combination modes. In a dynamic extraction system, the supercritical fluid continuously flows through the sample in the extraction vessel and out the restrictor to the trapping vessel.
- the supercritical fluid circulates in a loop containing the extraction vessel for some period of time before being released through the restrictor to the trapping vessel.
- a static extraction is performed for some period of time, followed by a dynamic extraction.
- the use of supercritical fluid extraction to obtain natural compounds and complexes is well known in the art. See, for instance. Natural Extracts Using Supercritical Carbon Dioxide, by Mamata Mukhopadhyay (CRC Press LLC, Boca Raton, Florida, 2000, ISBN 0-8493-0819-4).
- Therapeutically effective dose or amount A quantity of a substance, such as an antioxidant, sufficient to achieve a desired effect in a subject being treated.
- the effective amount of a specific substance will be dependent on the subject being treated, the severity of the affliction, and the manner of administration of the substance.
- the therapeutically effective amount of a substance such as the therapeutically effective amount of an antioxidant, can be determined by various methods, including generating an empirical dose-response curve, predicting potency and efficacy of a congener by using quantitative structure activity relationships (QSAR) methods or molecular modeling, and other methods used in the pharmaceutical sciences. Since oxidative damage is generally cumulative, there is no minimum threshold level (or dose) with respect to efficacy. However, minimum doses for producing a detectable therapeutic or prophylactic effect for particular conditions can be established.
- Astaxanthin Prevents DNA Oxidation in Immune Cells
- a method of reducing DNA cellular damage in vivo by administering an oral dose of natural astaxanthin extract to a subject.
- the natural astaxanthin extract is preferably in mono- and di-ester form, which is known to exhibit greater stability and intestinal absorption in comparison with free astaxanthin.
- the natural astaxanthin extract greatly reduces in vivo oxidative damage to the subjects' cells, especially cells of the immune system.
- Reported herein is a study of the role of dietary astaxanthin on immunity and oxidative status in healthy adult humans.
- OHdG OHdG after 4 weeks of feeding.
- This is particularly surprising not only because of the magnitude of the effect (>35% reduction in 8-OHdG), but also in light of prior report indicating that oral carotenoid supplementation did not have a significant effect on endogenous oxidative DNA damage (Collins et al, Carcinogenesis 19(12):2159-2162, 1998).
- a method for reducing for instance, by preventing, reversing, inhibiting, or ameliorating
- oxidative DNA damage in a subject, which method involves administering to the subject a therapeutically effective amount (or dose) of astaxanthin, particularly astaxanthin in the form of a natural extract.
- Astaxanthin is well known as the pigment providing the pinkish-red hue to the flesh of salmon and trout, as well the coloring in the carapaces of shrimp, lobsters and crayfish. As animals are unable to synthesize carotenoids, these animals obtain astaxanthin through the food chain from the sources which manufacture it.
- the structure of astaxanthin has been determined (Grangaud, Comt. Rend., 242, 1767, 1956; Andrews et al., Acta. Chem. Scand., B28, 730, 1974), and is as follows:
- astaxanthin is (3,3'- dihydroxy-beta,beta-carotene-4,4'-dione).
- the astaxanthin molecule has two asymmetric carbons located at the 3 and 3' positions of the benzenoid rings on either end of the molecule.
- Different enantiomers of the molecule result from the exact way that the hydroxyl groups (-OH) are attached to the carbon atoms at these centers of asymmetry.
- the hydroxyl group is attached so that it projects above the plane of the molecule, it is said to be in the R configuration; when the hydroxyl group projects below the plane of the molecule, it is said to be in the S configuration.
- 3R,3'R), (3S,3'S) and (3R,3'S; meso are shown in the following structures:
- This cis-trans or (E/Z)-isomerism of the carbon-carbon double bonds is another interesting feature of the stereochemistry of carotenoids, such as astaxanthin, because it has been demonstrated that the (E/Z)-isomers may have different biological properties. According to the number of double bonds, a great number of hypothetical (E/Z)-isomers exist for each carotenoid.
- the double bonds of the polyene chain can be divided into two groups: (I) double bonds with no steric hindrance of the (Z)-isomer (central 15,15'-double bond and the double bonds bearing a methyl group, such as the 9-, 9'-, 13-, and 13'-double bonds) and (2) double bonds with steric hindrance (7-, 7'-, 11-, and l l'-double bonds).
- (I) double bonds with no steric hindrance of the (Z)-isomer central 15,15'-double bond and the double bonds bearing a methyl group, such as the 9-, 9'-, 13-, and 13'-double bonds
- double bonds with steric hindrance (7-, 7'-, 11-, and l l'-double bonds 7.
- carotenoids occur in nature as the (all-E)-isomer, though exceptions are known. Some carotenoids readily undergo isomerization when isolated or otherwise manipulated; therefore (Z)-isomers that are described in the literature as natural products may be artifacts. In addition,
- (E/Z)-isomerization may occur when a carotenoid is kept in solution. Normally, the percentage of the (Z)-isomers is rather low, but it is enhanced at higher temperature, and the formation of (Z)-isomers is increased by exposure to light.
- ⁇ sterlie et al. (Abs. 2A-13; 12th Int. Symp on Carotenoids, Cairns, Queensland, AU, 1999) discusses the blood appearance and distribution of astaxanthin E/Z isomers amount plasma lipoproteins in humans administered a single meal of astaxanthin. Synthetically produced astaxanthin is normally present in unesterified form (i.e., diol). In nature, astaxanthin is often present as diesters.
- astaxanthin present as diester is more stable than free astaxanthin (Omara-Alwala et /., J Agric. Food Chem., 33:260, 1985; Arai et ⁇ t, Aquaculture, 66:255, 1987).
- esterified (mono- or diester, or a mixture thereof) astaxanthin is more biologically available/active. Astaxanthin and/or its ester can be chemically synthesized by any method for use in the compositions and methods described herein. Methods for synthesizing astaxanthin are established (Cooper et al, J. Chem. Soc. Perkin Trans.
- astaxanthin products are readily available, for instance, from DSM Nutritional Products (Basel, Switzerland) (formerly Roche Vitamins and Fine Chemicals), Bayer's chemical division (sold as Carophyll® pink; Roche Vitamins Japan KK, Tokyo, Japan), and BASF (sold as Lucantin® Pink; Mount Olive, New Jersey).
- DSM Nutritional Products Basel, Switzerland
- Bayer's chemical division sold as Carophyll® pink; Roche Vitamins Japan KK, Tokyo, Japan
- BASF sold as Lucantin® Pink; Mount Olive, New Jersey
- natural sources of astaxanthin are numerous, nearly all produce only very low concentrations.
- the green algae Haematococcus pluvialis provides the most concentrated natural source of astaxanthin known, from 10,000-40,000 ppm (mg/kg) astaxanthin.
- the flesh of wild Atlantic salmon on average contain 5 ppm of astaxanthin, Coho salmon about 14 ppm astaxanthin and sockeye salmon average 40 ppm (Turujman et al., JAOAC Int. 80(3):622-632, 1997).
- a typical gelcap comprising a 1 mg dose of astaxanthin from Haematococcus has the same amount of astaxanthin as 200 grams of Atlantic salmon. Astaxanthin and/or its ester, has been found in krill, in shrimp eggs (Kuhn et al. Angew. Chem.
- Astaxanthin can be extracted and purified from natural sources for use in the methods and compositions described herein. For instance, astaxanthin can be isolated from Haematococcus algae. Haematococcus occurs in nature worldwide, but is most often found in cooler pools of fresh water.
- Haematococcus is motile and utilizes the available nitrate, phosphate, and other nutrients to grow and reproduce.
- the alga form a protective cell wall and encyst. Massive amounts of astaxanthin are produced, and the cells undergo a dormant stage until the next influx of water and nutrients. Cells can remain viable in this encysted stage with the high level of protective astaxanthin for decades. Red cysts are significantly more resistant to photoinhibition and oxygen radicals than green cells, suggesting significant protective roles for astaxanthin (Kobayashi et al, J. Ferm. Bioeng. 74(l):61-63, 1992). United States Patent No.
- 5-68585 describes a method for obtaining a large amount of astaxanthin by inducing cyst formation in algae after aerobically culturing Haematococcus pluvialis.
- Japanese Unexamined Patent Publication No. 1-187082 describes methods for producing astaxanthin and/or its ester by culturing green algae able to biosynthesize astaxanthin, examples of which include Clamvdomonas, Haematococcus, Chlorocytrium, Chlorella, Chlorococcum, Characium, Trebouxia, Dictyosphaerium, Scenedesmus, and Hydrodictycm, in a medium containing sodium, potassium and rubidium salts. See also United States Patent No.
- Haematococcus algae has been reviewed by the US FDA and approved as a dietary supplement. It has also been approved in Japan for use in both foods and animal feeds. A different formulation of Haematococcus algae extract has gained wide acceptance in the aquiculture markets as a pigmentation and vitamin source for salmon, trout, shrimp and ornamental fish and has been approved as a feed additive for salmonids in Canada. Standard toxicity and safety studies have been conducted with Haematococcus algae.
- Acute oral toxicity studies were conducted on Charles River CD rats with a dosage level of 5 grams of Haematococcus algae/kg for 13 days. Groups were evaluated for mortality, pharmacotoxic signs, body weights, and necropsy examinations during the 13 -day study. The demonstrated LD 50 value of each lot was greater than the administered dose of 5 grams/kg. No visible abnormalities were observed, nor differences in body weights during the study. Postmortem examination did not reveal any abnormalities in rats sacrificed at the end of the study. A second clinical acute toxicity study with rats showed a LD 50 value higher than 12 grams/kg with no clinical, weight or behavioral abnormalities.
- Haematococcus algae extract is a safe and natural form of astaxanthin that has been shown to have excellent antioxidant properties.
- one Haematococcus algae extract that is useful in the current methods is ZANTHIN® Extract Astaxanthin Complex 10% Standardized (U.S. Nutra, LLC, Eustis, FL).
- Astaxanthin Complex > 10% (Quantified spectrophotometrically against standard [Sigma A9335] in acetone ( ⁇ max 478)), containing: Astaxanthin > 9.5%; Lutein ⁇ 0.1%; ⁇ -Carotene ⁇ 0.1%; Canthaxanthin ⁇ 0.1%; and Other Carotenoids ⁇ 0.2%.
- the ZANTHIN® Extract Astaxanthin Complex is prepared using a supercritical fluid (C0 2 ) extraction process (SuPure® C0 2 ) that produces a product containing no solvent residues.
- C0 2 supercritical fluid
- Another contemplated preparation comprising astaxanthin that is appropriate for use in methods described herein is astaxanthin in the form of an oleoresin concentrate from Haematococcus pluvialis, marketed as astaZanthinTM by La Haye Laboratories Inc., Redmond, WA.
- the ratios of components of this extract are believed to be similar to those listed above for ZANTHIN®.
- Astaxanthin also can be extracted from Adonis species plants (see, e.g., as disclosed in
- United States Patent No. 5,453,565 to Mawson, and Japanese Published Patent Publication No. 5- 509227), and from yeast see, e.g., United States Patent Nos. 5,346,810 and 5,972,642 to Fleno et al, Japanese Unexamined Patent Publication No. 3-206880, and Japanese Unexamined Patent Publication No. 4-228064).
- Methods for extracting astaxanthin and/or its ester from the shells of crustacean are described in United States Patent No. 4,505,936 to Meyers et al. and Japanese Unexamined Patent Publication No. 58-88353. Additional methods and refinements for extracting and/or purifying astaxanthin are described in the following: United States Patent No.
- Synthetic astaxanthin as discussed above, can be produced by various chemical methods and the synthetic processes result in a mixture of different stereoisomers. Biosynthesized astaxanthin as produced a number of different organisms also result in varying stereoisomeric/enantiomeric forms. These differences are highlighted in Table 2.
- Haematococcus derived form astaxanthin is that the naturally derived material mainly consists of mono and diesterified astaxanthin fatty acid esters. These are also the predominant form found in salmon species, and appear to be more bio- available (possibly because it is better absorbed). Many biological studies have been conducted on the different forms of Astaxanthin and studies by Naguib have shown that the Haematococcus astaxanthin containing extract is more potent anti oxidant in vitro than for example the synthetic form (Naguib, J. Agric. Food Chem, 48:1150-1154, 2000).
- Synthetic astaxanthin is also less stable to oxidative degradation, which reduces is effective shelf life unless it is stored under vacuum and or frozen.
- natural astaxanthin extract has several advantages. First, almost all of the material extracted from H. pluvialis is in the 3S, 3S' configuration, the identical isomeric form found in primarily nature, for instance, in salmon. Most of the experimental data on natural astaxanthin related to biological effectiveness has used this isomer. The Phaffia astaxanthin on the other hand is all 3R,3R. While found in nature, this form is a tiny fraction of the total found or produced by any organism. Few organisms utilize the 3R, 3R' form, but it has proven ability to color Atlantic salmon when used as a feed.
- Astaxanthin extracted from Haematococcus algae is primarily in the esterified form, both monoester and diester forms. Esters are chemically more stable than free astaxanthin.
- Phaffia yeast astaxanthin is non-esterified (all free, diol).
- Synthetic astaxanthin is comprised of all free, non- esterfied astaxanthin in all four possible chiral forms (a racemic mixture).
- the racemic mixture is comprised of four forms, 25% 3R,3R', 25% 3S,3S' and 50% in the meso, (3R,3S' & 3S,3R') forms. Thus, only about 25% of synthetic astaxanthin is in the same form found naturally in salmon.
- Natural extracted astaxanthin-enriched oleoresin such as that produced by U.S. Nutra, is in the most stable form of all, where 10% astaxanthin is dispersed in a solution of natural algal oil, comprised primarily of omega-3 and omega- 6 fatty acids.
- natural astaxanthin enriched extracts useful in the provided methods comprise predominantly esterified astaxanthin.
- an example of such an extract from Haematococcus species will contain the various forms of astaxanthin and other carotenoids in the following amounts (based on total astaxanthin present of between 81-99%): free astaxanthin 1-5%; astaxanthin monoesters 46-79%; astaxanthin diesters 10- 39%; ⁇ -carotene 0-5%; lutein 1-11%; canthaxanthin 0-5.5%; and other carotenoids 1-9%.
- Specific extracts will contain free astaxanthin at about 0.20-0.73%; astaxanthin monoesters at about 80-82%; and astaxanthin diesters at about 14.80- 16.60%.
- an extract containing astaxanthin and/or its ester obtained by any of these methods, or equivalent methods or other methods known to those of ordinary skill in the art, can be used in the described methods for inhibiting DNA damage.
- relatively crude extracts or powders containing astaxanthin and/or its ester which extract/powder has been suitably purified as necessary.
- the astaxanthin-containing extract in some embodiments will contain additional naturally-occurring carotenoids, which collection of total carotenoids in the extract can be referred to as a carotenoid complex or, more specifically (where astaxanthin is the predominant carotenoid in the complex), an astaxanthin complex of carotenoids.
- the astaxanthin preparation can be provided to the subject alone or in a formulation with one or more additional components.
- One possible, non-limiting, mechanism of action of astaxanthin is through its antioxidant activity. Through this antioxidant action, astaxanthin may be involved in aging, cardiovascular diseases, dermatology disorders, cancer, immune function, inflammation, gastrointestinal diseases, strength and endurance, ocular diseases (macular degeneration), and neurological (Parkinson's and Alzheimer's) diseases. Overproduction of reactive oxygen and nitrogen species can tip the oxidan antioxidant balance, resulting in the various diseases mentioned. Therefore, dietary antioxidants are needed to remove these harmful oxidative products that can destroy cell membranes, proteins and DNA.
- astaxanthin as a dietary carotenoid
- absorption rate It has been shown, for instance, that the concentration of astaxanthin in plasma was much higher than that of ⁇ -carotene lutein in mice fed the same amount of these carotenoids (Park et al, J. Nutr. 128: 1802-1806, 1998; Park et al., J. Nutr. 128:1650-1656, 1998).
- Oxidative DNA damage can be measured by any art known technique. Methods for assessing DNA damage are well known; see, for instance, Loft & Poulsen (Free Radic. Res. 33:S67- 83, 2000).
- the level of oxidative DNA damage in an organ or cell may be studied by measurement of modified bases in extracted DNA by immunohistochemical visualization, and from assays of strand breakage before and after treatment.
- Oxidatively modified nucleobases can be measured in the DNA and strand breaks can be detected by the comet assay, optionally with the use of repair enzymes introducing breaks at oxidized bases.
- the excretion rate represents the average rate of damage in the body, whereas the level of oxidized bases in DNA is a concentration measurement in the specific cells.
- the comet assay also called the 'Single Cell Gel Assay', is a well known technique to detect DNA damage and repair at the level of single cells. This technique was developed by Swedish researchers Ostling & Johansson (Biochem. Biophys. Res. Commun. 123:291-298, 1984), who demonstrated that DNA in one or a few cells embedded in low-melt agarose migrates out of the cell in an electrophoretic field in a pattern that is influenced by the extent of the DNA damage.
- the comet assay was later modified by Singh et al. (Exp. Cell Res., 175:184-191, 1988), and is now described as the alkaline comet assay.
- the comet assay is one of the most popular tests of DNA damage (e.g., single- and double-strand breaks, oxidative-induced base damage, and DNA- DNA/DNA-protein cross linking) detection by electrophoresis that has been developed.
- the assay is described and reviewed in the following references: McKelvey-Martin et al, Mutat. Res. 288: 47-63, 1993; Fairbairn et al, Mutat. Res. 339: 37-59, 1995; Anderson et al, Mutagenesis 13: 539-555, 1998; Rojas et al, J.
- the comet assay can be adapted in order to detect oxidized pyrimidines and purines (such as 8-oxo-guanine) by digestion of the embedded nucleoid samples with endonuclease III and formamidopyrmidine glycosylase (FPG), respectively.
- oxidized pyrimidines and purines such as 8-oxo-guanine
- 8-OHdG can be measured in DNA samples (such as lymphocyte DNA) and in urine (Wu et al, Clin. Chim. Ada. 39:1-9, 2004).
- DNA samples such as lymphocyte DNA
- urine Wu et al, Clin. Chim. Ada. 39:1-9, 2004.
- HPLC with electrochemical detection HPLC/ECD
- GC/ MS methods are widely used (see, e.g., Cadet et al, Free Radic. Biol. Med. 33:441-49, 2002; Cooke er al, Free Radic. Res. 32:381-397, 2000).
- Enzyme- linked immunosorbent assay (ELISA) techniques are also being employed (Santella, Cane. Epidemiol. Biomarkers Prev. 8:733-739, 1999).
- a reduction in oxidative DNA damage is any measurable reduction in oxidized DNA in a subject, or any measurable reduction in a marker for oxidized DNA.
- a reduction in oxidation DNA damage can be measured as reduction in the size of comet observed, using a comet assay, or a reduction in the level of an oxidative DNA product (such as 8- OHdG) in a subject, compared to a time before administration of the astaxanthin composition, or in comparison to a subject not receiving the astaxanthin composition.
- the reduction is a reduction in the endogenous level of oxidative DNA damage.
- methods provided herein will result in at least a 10% reduction in oxidative DNA damage.
- administration of the astaxanthin or astaxanthin- enriched extract results in at least a 15% reduction in oxidative DNA damage; at least 25% reduction, at least 30% reduction, at least 40% reduction, or more.
- the level of endogenous oxidative DNA damage is reduced by at least 20% or more, for instance, at least 25%, at least 30%, at least 40%, at least 50%, at least 60%, at least 75%, at least 80%, or more.
- the reduction in oxidative DNA damage may be transient, and is expected to be linked to the dosage and time (duration) of administration of the astaxanthin or astaxanthin-enriched extract. It is understood that a measured reduction in oxidative DNA damage may include outright prevention of the oxidative damage, reversal of damage that has already occurred, or a combination of these.
- the present disclosure includes a treatment or supplement that inhibits DNA oxidation in a subject such as an animal, for example a rat or human.
- the method includes administering astaxanthin (pure or in the form of an extract), or a combination of astaxanthin and one or more other pharmaceutical or nutritional agents, to the subject optionally in a pharmaceutically compatible carrier.
- the astaxanthin is administered in an effective amount to measurably reduce, prevent, inhibit, reverse or otherwise decrease oxidative DNA damage in a cell of the subject, for instance an immune cell.
- the treatment can be used prophylactically in any subject, since all subjects are exposed to oxidative damage through metabolic processes.
- the treatment can be supplied to a subject in a demographic group at significant risk for particular oxidative damage.
- Subjects can also be selected using more specific criteria, such as a definitive diagnosis of a condition leaving the subject prone to the depredations of oxidative DNA damage.
- the administration of any exogenous astaxanthin would inhibit the progression of the oxidation associated disease as compared to a subject to whom the astaxanthin was not administered.
- the antioxidant effect increases with the dose of astaxanthin.
- the vehicle in which the astaxanthin is delivered can include pharmaceutically acceptable compositions of astaxanthin using methods well known to those with skill in the art. Any of the common carriers, such as sterile saline or glucose solution, can be utilized with the drugs provided by the invention.
- routes of administration include but are not limited to oral, intracranial ventricular (icv), intrathecal (it), intravenous (iv), parenteral, rectal, topical ophthalmic, subconjunctival, nasal, aural, sub-lingual (under the tongue) and transdermal.
- the astaxanthin may be administered intravenously in any conventional medium for intravenous injection such as an aqueous saline medium, or in blood plasma medium.
- Such medium may also contain conventional pharmaceutical adjunct materials such as, for example, pharmaceutically acceptable salts to adjust the osmotic pressure, lipid carriers such as cyclodextrins, proteins such as serum albumin, hydrophilic agents such as methyl cellulose, detergents, buffers, preservatives and the like.
- United States Patent No. 6,132,790 to Schlipalius describes methods of making water miscible compositions comprising carotenoids, such as astaxanthin. Astaxanthin and/or its crude extract can be used directly after being dissolved in ethanol and diluted with water. It can also be prepared into a latex preparation.
- a latex preparation can be prepared by adding gallic acid, L-ascorbic acid (or its ester or salt), gum (e.g., locust bean gum, qua gum or gelatin), vitamin P (e.g., flavoids such as hesperidin, lutin, quercetine, catechin, thianidine and eliodictin or mixtares thereof) to the aqueous phase, or by adding astaxanthin, astaxanthin crude extract or a mixture thereof to the oil phase, and then adding glycerine fatty acid ester or oil, examples of which include vegetable seed oil, soy bean oil, corn oil and other routinely used liquid oils.
- gum e.g., locust bean gum, qua gum or gelatin
- vitamin P e.g., flavoids such as hesperidin, lutin, quercetine, catechin, thianidine and eliodictin or mixtares thereof
- astaxanthin astaxanthin crude extract or
- a high-speed agitator or homogenizer can be used to emulsify such compositions.
- Astaxanthin and/or its ester is substantially insoluble in water. It can be provided in capsules and the like, for instance by suspending the astaxanthin in oil directly or by way of incorporation with an emulsifier.
- the astaxanthin product can be used in a powder, for instance, it can be spray dried and provided in the form of a liquid or powder.
- United States Patent Nos. 6,976,575 and 5,827,539, both to Gellenbeck describe production of dry caroteno id-oil powders.
- solubility of astaxanthin in oil is extremely low, although considerable time is required to dissolve crystals of astaxanthin in oil, the dissolution rate can be increased by using fine crystals.
- the solubility of astaxanthin is greater when heated to about 100°C or above. Esters of astaxanthin are highly soluble in, and can be easily dissolved in, oils.
- oils examples include vegetable oils such as soy bean oil, corn oil, rape seed oil, palm oil, olive oil, safflower oil, lemon oil, orange oil, peanut oil and sunflower oil, hardened oils produced by hydrogenating these oils, natural waxes such as lanolin, whale wax and bees wax, animal fats such as beef tallow, pork tallow and butter as well as wheat germ oil and concentrated vitamin E oil.
- vegetable oils such as soy bean oil, corn oil, rape seed oil, palm oil, olive oil, safflower oil, lemon oil, orange oil, peanut oil and sunflower oil
- hardened oils produced by hydrogenating these oils natural waxes such as lanolin, whale wax and bees wax
- animal fats such as beef tallow, pork tallow and butter as well as wheat germ oil and concentrated vitamin E oil.
- compositions comprising compositions, including food and pharmaceutical compositions, that can be prepared with optional conventional acceptable carriers, adjuvants and/or counterions as would be known to those of ordinary skill in the art.
- Suitable excipients include, e.g., organic and inorganic substances that are appropriate for enteral, parenteral, or oral administration, e.g., water, saline, buffers, vegetable oils, mineral oils, benzyl alcohol, cyclodextrin, hydroxypropylcyclodextrin (for instance, beta- hydroxypropylcyclodextrin), polyethylene glycols, glycerol triacetate and other fatty acid glycerides, gelatin, soya lecithin, carbohydrates such as lactose or starch or other sugars, magnesium stearate, talc or cellulose.
- the preparations can be sterilized and/or contain additives, such as preservatives or stabilizers.
- Astaxanthin can be formulated with various oils, including coconut, sunflower, mustard, almond, sesame, safflower, or peanut.
- oils can vary and in various embodiments include virtually any edible or consumable oil, particularly vegetable oils including but not limited to natural oils, such as omega-3 and omega-6 fatty acids found in the Haematococcus algae, rice bran oil, olive oil, cranberry seed oil, or mixtures of two or more thereof.
- compositions in some embodiments are in the form of a unit dose in solid, semi-solid and liquid dosage forms such as tablets, pills (such as enteric-coated pills), capsules, powders, stabilized beadlets (which optionally are compressed into a tablet or other form), granules, suppositories, liquid solutions or suspensions, injectable and infusible solutions.
- the dose varies according to the purpose of administration and status of the patient (sex, age, body weight and so forth), the normal adult dose as astaxanthin in the case of oral administration is 0.1 mg (100 ⁇ g) to 10 g per day and preferably 0.1 mg (100 ⁇ g) to 1 g per day.
- the range for obtaining preventive effects is 0.01 mg (10 ⁇ g) to 100 mg per day, for instance about 0.1 mg (100 ⁇ g) to 10 mg per day.
- Specific example daily dosages include 500 ⁇ g, 1 mg, 2 mg, 3 mg, 4, mg, 6 mg, 8 mg, 10 mg, and so forth, for instance to be provided to an adult human.
- dosages in some embodiments are applied in order to raise the plasma astaxanthin in the subject above a steady state level for a period of time, for instance, for a period of at least one week, or more. Steady state astaxanthin in many subjects is often essentially undetectable when measured by HPLC.
- dosages of astaxanthin are administered to a subject to increase the plasma astaxanthin level to at least 0.05 ⁇ mol/L ( ⁇ molar, or ⁇ M).
- the level is increased to at least 0.06 ⁇ M, at least 0.08 ⁇ M, at least 0.1 ⁇ M, at least 1.2 ⁇ M, at least 1.4 ⁇ M or more.
- the level of astaxanthin is maintained for more than a week, for instance, for at least two weeks, at least a month, or longer. In some instances, it is beneficial to continue maintenance of the astaxanthin dosage, and therefore the level of astaxanthin in the subject's system, for periods measured in months or years.
- a compound such as astaxanthin
- esters are to s esters, such as ethyl esters, or esters with long chain fatty acids, such as lauric, myristic or palmitic esters, or naturally occurring esters. All forms can be provided to a subject individually or a mixture of forms obtained from natural products or compositions synthetically produced. The preparations and methods described herein can be utilized in both human and veterinary medicine.
- the disclosure provides a food supplement or pharmaceutical composition, which composition comprises astaxanthin or an ester thereof together with a food supplement or pharmaceutically accepted diluent or carrier.
- the astaxanthin may be used together with other active agents, such as, for example: another carotenoid (e.g., lycopene or alpha, beta, gamma or delta carotene), one or more other antioxidants (such as vitamin A, vitamin C, vitamin E ( ⁇ - tocopherol and other active tocopherols)), selenium, copper, zinc, manganese and/or ubiquinone (coenzyme Q10).
- another carotenoid e.g., lycopene or alpha, beta, gamma or delta carotene
- one or more other antioxidants such as vitamin A, vitamin C, vitamin E ( ⁇ - tocopherol and other active tocopherols)
- selenium copper, zinc, manganese and/or ubiquinone (coenzyme Q10).
- oral astaxanthin can be partially destroyed in the gastrointestinal tract, thereby lowering the effectively applied dosage.
- the inhibitor may be included as part of a composition as part of a composition described herein, or administered separately.
- This example provides a description of effects of oral astaxanthin on the immune system of human adults, when taken at 2 mg or 8 mg per day.
- the astaxanthin was administered in the form of one soft gel capsule taken every morning. Blood was again drawn on week 0, 4 and 8 to assess immune function and oxidative status. HPLC. Astaxanthin content in plasma was analyzed by reverse phase HPLC (Alliance 2690 Waters HPLC system fitted with a photodiode array detector, Waters, Milford, MA) as previously described (Park et al., JNutr. 128(10):1650-1656, 1998). See Fig. 1 and Table 3. Trans- ⁇ -apo- $ 8'carotenal (Sigma Chem. Co., St. Louis, MO) was used as the internal standard.
- Delayed-type hypersensitivity Delayed-type hypersensitivity (DTH) response to an intracutaneous injection of tuberculin (Mono-Vacc Test (O.T.), Pasteur Merieux Connaught, France) was assessed on week 8. The injection was administered by a physician and skin thickness and induration were measured at 0, 24, 48 and 72 hours after challenge. In general, DTH response was maximal at 48 to 72 h post-injection (Fig. 9). Subjects fed 2 mg astaxanthin had higher (P ⁇ 0.08) DTH response than unsupplemented controls. Those fed 8 mg astaxanthin did not show a similar heightened DTH response. Lymphoproliferation.
- PBMC peripheral blood mononuclear cell
- Con A concanavalin A
- PWM pokeweed mitogen
- Oxidative damage to DNA. 8-Hydroxy-2'-deoxyguanosine (8-OHdG) was measured in plasma by ELISA (BIOXYTECHTM 8-OHhdG-EIA Kit, OxisResearch, Portland, OR; sensitivity 0.5 ⁇ g/L).
- Table 4 Average Levels of 8-OHdG O mg 2 mg 8 mg 0 week 21.6 23.4 23.5 4 week 21.5 13.8 15.3 8 week 21.7 14.4 13.2
- Plasma concentrations of 8-epi-prostaglandin F2 ⁇ (8-isoprostane) was measured by ELISA. Astaxanthin did not significantly influence lipid peroxidation measured in the plasma (Fig. 11).
- Statistics. Data were analyzed by repeated measures ANOVA using the General Linear Model of SAS (1991). Differences among treatment means were compared by a protected LSD test and considered different at P ⁇ 0.05.
- Dietary astaxanthin enhanced both cell-mediated and humoral immune responses in healthy human subjects.
- the immune markers significantly enhanced by feeding astaxanthin included T and B cell mitogen-induced lymphoproliferation and NK cell cytotoxic activity. Enhancement of these ex vivo immune markers was supported by the observed increases in the total number of T and B cells as analyzed by flow cytometry.
- the tuberculin DTH test (a reliable clinical test to assess in vivo T cell function; Miyamoto et al, J. Vet. Med. Sci. 57: 347-349, 1995) also was elevated in subjects given 2 mg astaxanthin. All these immune responses were generally observed after 8 weeks of supplementation, after cutaneous tuberculin injection.
- Natural killer cells serve in an immuno-surveillance capacity against tumors. Therefore, the observed enhancement of NK cell cytotoxic activity with dietary astaxanthin suggests that this ketocarotenoid may play a role in cancer etiology.
- Others have reported increased cytotoxic T lymphocyte activity and IFN- ⁇ production in astaxanthin-fed mice (Jyonouchi et al, Nutr. Cancer 36: 59-65, 2000).
- dietary lutein increased IFN- ⁇ mRNA expression but decreased the expression of IL-10 in splenocytes of tumor-bearing mice; these changes paralleled the inhibitory action of lutein against tumor growth (Cerveny et al, FASEB J. 13:A210, 1999).
- astaxanthin also increased the ex vivo antibody response of splenocytes to T-cell antigens (Jyonouchi et al, Nutr. Cancer 21 : 47-58, 1994). Astaxanthin may function to protect circulating blood cells through its antioxidant action (Martin et al, J. Prakt. Chem. 341-: 302-308, 1999; Naguib, J. Agric. Food Chem. 48: 1150-1154, 2000).
- Example 2 Obtaining a Natural Astaxanthin-Enriched Extract This example provides one method for obtaining a natural astaxanthin-enriched extract from
- Clean food-grade carbon dioxide (without chemical co- solvents or entrainers) in the supercritical state is passed through the extraction baskets, to load astaxanthin, other carotenoids, and lipids from the algal meal into the C0 2 .
- the "loaded” carbon dioxide passes through a back-pressure regulator into a separation vessel under lower pressure and temperature, to transfer the carbon dioxide into the gas phase and separate it from the astaxanthin- enriched carotenoid oleoresin.
- the extract is then drawn off from the separation vessel through a valve and collected in, for instance, portable stainless steel vessels. Beneficially, the carbon dioxide can be recovered and recycled. Fully extracted (spent) algal meal (which may have been extracted more than once with C0 2 ) is removed from the basket to complete the extraction process.
- Astaxanthin-complex carotenoid oleoresin collected form the separation vessel can be analyzed for astaxanthin and other carotenoid content, and then packaged in sealed airtight food- grade containers (for instance, made from HDPE). It is optimally stored at low temperature (e.g., 2- 10 °C)
- astaxanthin particularly in the form of a natural astaxanthin-enriched extract
- the disclosure further provides methods of applying astaxanthin, or a preparation comprising astaxanthin, to subjects in order to reduce, inhibit, prevent, or otherwise decrease oxidative DNA damage in a cell of the subject. It will be apparent that the precise details of the methods described may be varied or modified without departing from the spirit of the described invention. We claim all such modifications and variations that fall within the scope and spirit of the claims below.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04779380A EP1684776A1 (en) | 2003-07-25 | 2004-07-26 | Natural astaxanthin extract reduces dna oxidation |
US10/565,717 US20060217445A1 (en) | 2003-07-25 | 2004-07-26 | Natural astaxanthin extract reduces dna oxidation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49012103P | 2003-07-25 | 2003-07-25 | |
US60/490,121 | 2003-07-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005011712A1 true WO2005011712A1 (en) | 2005-02-10 |
Family
ID=34115359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/024314 WO2005011712A1 (en) | 2003-07-25 | 2004-07-26 | Natural astaxanthin extract reduces dna oxidation |
Country Status (3)
Country | Link |
---|---|
US (1) | US20060217445A1 (en) |
EP (1) | EP1684776A1 (en) |
WO (1) | WO2005011712A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1867327A1 (en) | 2006-06-16 | 2007-12-19 | Yamaha Hatsudoki Kabushiki Kaisha | Astaxanthin and esters thereof for protecting neurocytes and treating Parkinson's disease |
US7851199B2 (en) | 2005-03-18 | 2010-12-14 | Microbia, Inc. | Production of carotenoids in oleaginous yeast and fungi |
WO2011050474A1 (en) | 2009-10-29 | 2011-05-05 | Acasti Pharma, Inc. | Concentrated therapeutic phospholipid compositions |
US8691555B2 (en) | 2006-09-28 | 2014-04-08 | Dsm Ip Assests B.V. | Production of carotenoids in oleaginous yeast and fungi |
WO2016146803A1 (en) * | 2015-03-19 | 2016-09-22 | Basf Se | Astaxanthin compositions (iii) |
WO2022091995A1 (en) * | 2020-10-26 | 2022-05-05 | Eneos株式会社 | Composition for functional food including cis-astaxanthin |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090297492A1 (en) * | 2008-05-30 | 2009-12-03 | Yamaha Hatsudoki Kabushiki Kaisha | Method for Improving Cognitive Performance |
US9763897B2 (en) | 2010-04-30 | 2017-09-19 | U.S. Nutraceuticals, LLC | Therapeutic astaxanthin and phospholipid composition and associated method |
US20140205627A1 (en) * | 2010-04-30 | 2014-07-24 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Composition and method to improve blood lipid profiles and reduce low density lipoprotein (ldl) per-oxidation in humans using algae based oils and astaxanthin |
US8663704B2 (en) * | 2010-04-30 | 2014-03-04 | U.S. Nutraceuticals, LLC | Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans |
EP2658983A2 (en) * | 2010-12-31 | 2013-11-06 | Direvo Industrial Biotechnology GmbH | Extraction of scenedesmus cell components |
US9173915B1 (en) | 2014-10-10 | 2015-11-03 | Peter F. Kador | Antioxidant eye drops |
WO2016146802A1 (en) * | 2015-03-19 | 2016-09-22 | Basf Se | Astaxanthin compositions (ii) |
WO2016146804A1 (en) * | 2015-03-19 | 2016-09-22 | Basf Se | Astaxanthin compositions (iv) |
CN105254551B (en) * | 2015-11-10 | 2017-08-25 | 中国中医科学院中药研究所 | The method of rapid extraction astaxanthin from haematococcus pluvialis |
CN105503684B (en) * | 2016-01-27 | 2018-02-02 | 华南理工大学 | A kind of supercritical CO2The method for extracting Astaxanthin In Haematococcus Pluvialis |
IL248150B (en) | 2016-09-29 | 2018-05-31 | Garti Nissim | Method for selective extraction of cannabinoids from a plant source |
IL248149B (en) | 2016-09-29 | 2020-03-31 | Garti Nissim | Dilutable formulations of cannbinoids and processes for their preparation |
IL248148B (en) * | 2016-09-29 | 2021-09-30 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Method for extraction of an agent from a plant source |
CN107156545B (en) * | 2017-05-23 | 2021-05-07 | 集美大学 | Bee bread containing astaxanthin and hydrophilic colloid and preparation method thereof |
US20190141924A1 (en) * | 2017-11-13 | 2019-05-16 | Arevik Minasyan | Relatively inexpensive process to turn green cells of Haematococcus pluvialis into astaxanthin accumulating red cysts |
US20190313681A1 (en) * | 2017-11-17 | 2019-10-17 | Jacob Rosenstein | Nutraceutical Composition for Telomere Lengthening, Reduction of DNA Damage, and Reduction of UV-Induced Skin Aging |
WO2020178821A1 (en) * | 2019-03-03 | 2020-09-10 | Algatechnologies Ltd. | Compositions comprising algae powder and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0249091A (en) * | 1988-08-11 | 1990-02-19 | Suntory Ltd | Astaxanthin-containing composition |
WO1996013255A1 (en) * | 1994-10-27 | 1996-05-09 | Board Of Trustees Of The University Of Illinois | Use of astaxanthin for retarding and ameliorating central nervous system and eye damage |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11511167A (en) * | 1995-08-14 | 1999-09-28 | オキシジェン インコーポレイティド | Carotenoid-nicotinamide-zinc composition and therapeutic method using the same |
JPH09124470A (en) * | 1995-10-26 | 1997-05-13 | Suntory Ltd | Antistress composition |
ATE301937T1 (en) * | 1999-05-27 | 2005-09-15 | Iams Company | METHOD FOR PRODUCING A PRODUCT FOR INCREASING THE IMMUNE RESPONSE IN PETS USING A COMBINATION OF ANTIOXIDANTS |
US6344214B1 (en) * | 1999-12-13 | 2002-02-05 | Cyanotech Corporation | Method for retarding and ameliorating fever blisters and canker sores |
US6258855B1 (en) * | 2000-02-08 | 2001-07-10 | Cyanotech Corporation | Method of retarding and ameliorating carpal tunnel syndrome |
US6277417B1 (en) * | 2000-04-07 | 2001-08-21 | Triarco Industries, Inc. | Method of inhibiting 5α-reductase with astaxanthin |
US6433025B1 (en) * | 2000-04-13 | 2002-08-13 | Cyanotech Corporation | Method for retarding and preventing sunburn by UV light |
US20040151761A1 (en) * | 2003-02-05 | 2004-08-05 | The Procter & Gamble Company | Methods and compositions utilizing astaxanthin |
-
2004
- 2004-07-26 EP EP04779380A patent/EP1684776A1/en not_active Withdrawn
- 2004-07-26 US US10/565,717 patent/US20060217445A1/en not_active Abandoned
- 2004-07-26 WO PCT/US2004/024314 patent/WO2005011712A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0249091A (en) * | 1988-08-11 | 1990-02-19 | Suntory Ltd | Astaxanthin-containing composition |
WO1996013255A1 (en) * | 1994-10-27 | 1996-05-09 | Board Of Trustees Of The University Of Illinois | Use of astaxanthin for retarding and ameliorating central nervous system and eye damage |
Non-Patent Citations (8)
Title |
---|
CHEW BOON P ET AL: "A comparison of the anticancer activities of dietary beta-carotene, canthaxanthin and astaxanthin in mice in vivo", ANTICANCER RESEARCH, vol. 19, no. 3A, May 1999 (1999-05-01), pages 1849 - 1854, XP008040144, ISSN: 0250-7005 * |
CRONIN J R: "The potential of astaxanthin: A new multipurpose, high-power antioxidant", ALTERNATIVE AND COMPLEMENTARY THERAPIES 2002 UNITED STATES, vol. 8, no. 1, 2002, pages 44 - 49, XP008040145, ISSN: 1076-2809 * |
DATABASE WPI Section Ch Week 199013, Derwent World Patents Index; Class B05, AN 1990-096261, XP002309715 * |
GUERIN M ET AL: "Haematococcus astaxanthin: applications for human health and nutrition", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 5, May 2003 (2003-05-01), pages 210 - 216, XP004422156, ISSN: 0167-7799 * |
KURASHIGE M ET AL: "INHIBITION OF OXIDATIVE INJURY OF BIOLOGICAL MEMBRANES BY ASTAXANTHIN", PHYSIOLOGICAL CHEMISTRY AND PHYSICS AND MEDICAL NMR, XX, US, vol. 22, 1990, pages 27 - 38, XP002945512, ISSN: 0748-6642 * |
NISHIGAKI IKUO ET AL: "Suppressive effect of astaxanthin on lipid peroxidation induced in rats", JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, vol. 16, no. 3, 1994, pages 161 - 166, XP008040155, ISSN: 0912-0009 * |
OHGAMI KAZUHIRO ET AL: "Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo.", IOVS, vol. 44, no. 6, June 2003 (2003-06-01), pages 2694 - 2701, XP002309714 * |
SARRAFIZADEH R ET AL: "New therapies for the treatment of age-related macular degeneration", EXPERT OPINION ON THERAPEUTIC PATENTS 2000 UNITED KINGDOM, vol. 10, no. 3, 2000, pages 333 - 341, XP002309713, ISSN: 1354-3776 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7851199B2 (en) | 2005-03-18 | 2010-12-14 | Microbia, Inc. | Production of carotenoids in oleaginous yeast and fungi |
US9909130B2 (en) | 2005-03-18 | 2018-03-06 | Dsm Ip Assets B.V. | Production of carotenoids in oleaginous yeast and fungi |
US8288149B2 (en) | 2005-03-18 | 2012-10-16 | Dsm Ip Assets B.V. | Production of carotenoids in oleaginous yeast and fungi |
EP1867327A1 (en) | 2006-06-16 | 2007-12-19 | Yamaha Hatsudoki Kabushiki Kaisha | Astaxanthin and esters thereof for protecting neurocytes and treating Parkinson's disease |
US8691555B2 (en) | 2006-09-28 | 2014-04-08 | Dsm Ip Assests B.V. | Production of carotenoids in oleaginous yeast and fungi |
US9297031B2 (en) | 2006-09-28 | 2016-03-29 | Dsm Ip Assets B.V. | Production of carotenoids in oleaginous yeast and fungi |
EP2493478A1 (en) * | 2009-10-29 | 2012-09-05 | Acasti Pharma, Inc. | Concentrated therapeutic phospholipid compositions |
EP2493478A4 (en) * | 2009-10-29 | 2013-02-27 | Acasti Pharma Inc | Concentrated therapeutic phospholipid compositions |
US9475830B2 (en) | 2009-10-29 | 2016-10-25 | Acasti Pharma Inc. | Concentrated therapeutic phospholipid compositions |
WO2011050474A1 (en) | 2009-10-29 | 2011-05-05 | Acasti Pharma, Inc. | Concentrated therapeutic phospholipid compositions |
EP3335713A1 (en) * | 2009-10-29 | 2018-06-20 | Acasti Pharma, Inc. | Concentrated therapeutic phospholipid compositions |
US10130644B2 (en) | 2009-10-29 | 2018-11-20 | Acasti Pharma Inc. | Concentrated therapeutic phospholipid compositions |
US10617702B2 (en) | 2009-10-29 | 2020-04-14 | Acasti Pharma Inc. | Concentrated therapeutic phospholipid compositions |
WO2016146803A1 (en) * | 2015-03-19 | 2016-09-22 | Basf Se | Astaxanthin compositions (iii) |
WO2022091995A1 (en) * | 2020-10-26 | 2022-05-05 | Eneos株式会社 | Composition for functional food including cis-astaxanthin |
Also Published As
Publication number | Publication date |
---|---|
US20060217445A1 (en) | 2006-09-28 |
EP1684776A1 (en) | 2006-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060217445A1 (en) | Natural astaxanthin extract reduces dna oxidation | |
AU2011260037B2 (en) | Dietary formulations | |
JP6141929B2 (en) | Compositions containing anthocyanidins and methods of use | |
Cao et al. | Dietary astaxanthin: an excellent carotenoid with multiple health benefits | |
Patil et al. | Pharmaceutical and nutraceutical potential of natural bioactive pigment: astaxanthin | |
Tejera et al. | Pigmentation, carotenoids, lipid peroxides and lipid composition of skin of red porgy (Pagrus pagrus) fed diets supplemented with different astaxanthin sources | |
US6344214B1 (en) | Method for retarding and ameliorating fever blisters and canker sores | |
Beltrán et al. | Dietary dehydrated lemon peel improves the immune but not the antioxidant status of gilthead seabream (Sparus aurata L.) | |
EP1755406B1 (en) | Compositions for reducing oxidative stress in an animal | |
JP2009517482A (en) | Nutritional supplement composition of algae and algae extract | |
WO1995000130A1 (en) | Use of hydrophilic carotenoids for the manufacture of a medicament for the treatment of diseases having an oxygenation mechanism | |
JP2009541389A (en) | Extracts of Aphanizomenon Flos Aquae and nutritional, cosmetic and pharmaceutical compositions containing the same | |
JP2016520540A (en) | Neuroprotective effects of carotenoids in the brain | |
López-Cervantes et al. | Astaxanthin, lutein, and zeaxanthin | |
Olabiyi et al. | Palm oil and ground nut oil supplementation effects on blood glucose and antioxidant status in alloxan-induced diabetic rats | |
Chow et al. | The effect of dietary carotenoids of different forms: microemulsified and non-microemulsified on the growth performance, pigmentation and hematological parameters in hybrid catfish (Clarias macrocephalus× Clarias gariepinus) | |
Meziane et al. | Bioavailability of natural and synthetic vitamins: A significant difference on Oxidative Stress Status (OSS) | |
Olaizola | 13 The Production and Health Benefits of Astaxanthin | |
AU762968B2 (en) | Compounds useful in reducing the level of insulin like growth factor-1 (IGF-1) in blood | |
Balaji | Spirulina-small but a spectacular species | |
EP4279068A1 (en) | Composition comprising a combination of capsaicin and/or phenylcapsaicin and astaxanthin for the prevention and treatment of inflammatory-based skin diseases, in particular associated with skin aging | |
Akkewar et al. | A mechanistic review on growing multiple therapeutic applications of lutein and its global market research | |
Majumder et al. | ASTAXANTHIN: A PROMISING ANTIOXIDANT TO AMELIORATE HEAT STRESS AND IMPROVE PRODUCTION POTENTIAL IN ANIMALS. | |
Reznick et al. | Vitamin E and the aging process | |
Cronin | The potential of astaxanthin: A new multipurpose, high-power antioxidant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006217445 Country of ref document: US Ref document number: 10565717 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004779380 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004779380 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10565717 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004779380 Country of ref document: EP |